<DOC>
	<DOC>NCT02722551</DOC>
	<brief_summary>Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve</brief_summary>
	<brief_title>CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study</brief_title>
	<detailed_description>The study is a multi-center, prospective, single-arm, and non-randomized study designed to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve with transapical and transseptal delivery systems in patients with degenerative or functional/ischemic mitral regurgitation.</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>NYHA ≥ II Moderate/severe or severe mitral regurgitation Prohibitive risk for openheart surgery Meets anatomical criteria Unsuitable anatomy Need for emergent or urgent surgery Prior mechanical aortic valve replacement Any prior surgical or transcatheter repair (excluding balloon valvuloplasty) or replacement of the mitral valve Preexisting device in the left ventricular apex Clinically significant, untreated coronary artery disease Limited life expectancy (&lt; 12 months) Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mitral</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>Insufficiency</keyword>
	<keyword>Degenerative</keyword>
	<keyword>Functional</keyword>
	<keyword>Primary</keyword>
	<keyword>Secondary</keyword>
	<keyword>Organic</keyword>
	<keyword>Transcatheter</keyword>
	<keyword>TMVR</keyword>
	<keyword>TMVI</keyword>
	<keyword>Heart valve</keyword>
	<keyword>Mitral valve</keyword>
	<keyword>Transapical</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>Trans-septal</keyword>
	<keyword>Transeptal</keyword>
	<keyword>Severe</keyword>
</DOC>